



Crosslinking Hyaluronic Acid within Skin

Transformable HA to Transformational Products

Doug Levinson, CEO, Co-founder
doug@fountbio.com

IMCAS

WORLD CONGRESS

PARIS
PALAIS DES CONGRÈS



Market Opportunity





Fine lines/wrinkles
Smoothness
Radiance



- Benefits
- Durability
- Tolerability
- Downtime
- Treatment


World's First Products that *Build* Crosslinked Hyaluronic Acid *within Skin*




Click chemistry




World's First Products that ***Build*** Crosslinked Hyaluronic Acid ***within Skin***




Clinical Product Concept: “FĪ-Derm”




Crosslinked HA
“FI $\bar{\text{T}}$ -HA $_{\text{XL}}$ ”



High Levels of
Crosslinked HA
Delivered per
 cm^2



Fluorescence
FLI-HA_{XL}



Surface


250μm
depth line

*Aesthetic
Zone*


50 μm

Immediate and Durable Benefits

- No TRAEs
- Benefits:
 - Immediate
 - Long-lasting
 - Bio-stimulation
- 100% double-blind treatment
- No anaesthesia



Modified Fitzpatrick Wrinkle Scale (% subjects with improvement)



Bridge Across Aesthetics and Consumer Beauty Markets



Aesthetics



Clinic Med Spa Retail Home


SKINCEUTICALS
ADVANCED SKINCARE BACKED BY SCIENCE

ALASTIN
SKINCARE



Consumer

Projected Manufacturer's Revenue (US Market, 5 years Post-launch)



- High margins
- Reduced COGS
- Multiple revenue streams


On Track to US IDE Feasibility (PhII) Study



- Series B financing secured
- Clear clinical and regulatory path
- Preclinical development on track
- Submission of IDE for large PhII study in 12-18 mos
 - 100 subjects


Product Innovation Platform

In situ
crosslinking




Product Innovation Platform

In situ
crosslinking Precise
Localization





Product Innovation Platform

In situ Precise Microneedle
crosslinking Localization Delivery



+ Active Ingredients





Thank You!